Utmost Group PLC (TLSI) files Schedule 13G showing 5.71% ownership
Rhea-AI Filing Summary
TriSalus Life Sciences, Inc. Schedule 13G reports that Utmost Group PLC beneficially owns 3,503,385 shares of common stock, equal to 5.71% of the class as of 03/31/2026. The filing notes ownership declined by more than 1% versus 09/30/2025 due to an increase in outstanding shares. The report is signed by Ian Maidens, Group CFO, on 05/05/2026.
Positive
- None.
Negative
- None.
Insights
Utmost Group PLC holds a 5.71% stake in TriSalus as of 03/31/2026.
Utmost Group PLC reports sole voting and dispositive power over 3,503,385 shares, representing 5.71% of the class. The filing explicitly ties a >1% ownership decline to an increase in outstanding shares between 09/30/2025 and 03/31/2026.
Cash‑flow treatment or planned dispositions are not disclosed in the excerpt; subsequent filings would state any sale programs or schedules.
The Schedule 13G is a passive reporting format by a regulated non‑U.S. institution.
The filer indicates reliance on a foreign regulatory scheme and certifies comparability to specified U.S. equivalents. The filing includes identification of a subsidiary, Utmost Luxembourg S.A., and is signed by the Group CFO on 05/05/2026.
This is a disclosure of beneficial ownership; it does not, by itself, signal trading intent.
Key Figures
Key Terms
Schedule 13G regulatory
beneficially owned regulatory
sole dispositive power regulatory
foreign regulatory scheme regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.